New drug combo shows promise for Hard-to-Treat CLL

NCT ID NCT03467867

Ongoing Disease control Sponsor: Georgetown University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase II study tests a combination of two drugs, venetoclax and rituximab, in 25 people with chronic lymphocytic leukemia (CLL) that has relapsed or not responded to treatment. The goal is to see how well the combination works and how safe it is. Participants receive venetoclax pills and rituximab injections, and researchers measure tumor shrinkage and how long the response lasts.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: venetoclax and rituximab
What this could lead to: If successful, this combination could offer a new treatment option for people with CLL that has come back or not responded to prior therapy.
What could go wrong: This is a small, early-phase study (25 people) with no control group, so results may not apply broadly. Side effects from the drugs are possible, and the treatment may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell chronic lymphocytic leukemia leukemia lymphoproliferative syndrome neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CHRONIC LYMPHOCYTIC LEUKEMIA

Contacts and locations

Show contact details

Locations

Georgetown University Medical Center

Washington D.C., District of Columbia, 20007, United States
John Theurer Cancer Center at Hackensack University Medical Center

Hackensack, New Jersey, 07601, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.